Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Barasertib

Alternative Names: barasertib, azd1152
Latest Update: 2024-05-06
Latest Update Note: PubMed Publication

Product Description

An orally bioavailable, small-molecule, dihydrogen phosphate prodrug of the pyrazoloquinazoline Aurora kinase inhibitor AZD1152-hydroxyquinazoline pyrazol anilide (AZD1152-HQPA) with potential antineoplastic activity.  (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/barasertib)

Mechanisms of Action: AURK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Acute Myeloid Leukemia

Phase 2: Acute Myeloid Leukemia|Diffuse Large B-Cell Lymphoma

Phase 1: Acute Myeloid Leukemia|Oncology Solid Tumor Unspecified|Leukemia|Other

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
AZD1152 in diffuse large B-cell lymphoma

P2

Completed

Diffuse Large B-Cell Lymphoma

2013-09-09

ORH/PID/6265

P2

Completed

Diffuse Large B-Cell Lymphoma

2013-09-01

2009-010114-30

P2

Terminated

Acute Myeloid Leukemia

2012-04-26

SPARK-AML1

P3

Completed

Acute Myeloid Leukemia

2011-06-01

LDAC

P1

Completed

Acute Myeloid Leukemia

2010-08-01

D1531C00012

P1

Completed

Acute Myeloid Leukemia

2010-06-01

D1531C00007

P1

Completed

Acute Myeloid Leukemia

2009-10-01

D1531C00008

P1

Completed

Acute Myeloid Leukemia

2009-08-01

D1531C00002

P1

Completed

Oncology Solid Tumor Unspecified

2008-06-06

D1531C00001

P1

Terminated

Oncology Solid Tumor Unspecified

2008-06-01

JapicCTI-090957

P2

Completed

Acute Myeloid Leukemia

None

JapicCTI-080508

P1

Completed

Leukemia

None

D1531C00003

P1

Terminated

Other

None

Recent News Events

Date

Type

Title

05/06/2024

PubMed

 AURKB promotes colorectal cancer progression by triggering the phosphorylation of histone H3 at serine 10 to activate CCNE1 expression.

04/01/2024

PubMed

 Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells.

01/22/2024

PubMed

 Aurora B facilitates cholangiocarcinoma progression by stabilizing c-Myc.

06/24/2021

News Article

 Anavo Therapeutics Strengthens Scientific Advisory Board with Industry-Leading Drug Discovery Experts in Oncology

04/03/2019

News Article

 Sierra Reports Late-Breaking SRA141 Preclinical Data in Poster at AACR 2019

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions